UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section  
13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 20,    
2020 Johnson & Johnson (Exact name of registrant as specified in its charter)                                      
                                                                                                  
  New Jersey                         1-3215                     22-1024240                        
  (State or Other Jurisdiction of    -Commission File Number    -IRS Employer Identification No.  
  Incorporation)                                                                                  
                                                                                                  
One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933 (Address of Principal Executive Offices) (Zip Code)   
Registrant’s telephone number, including area code: 732- 524-0400 Check the appropriate box below if the Form      
8-Kfiling is intended to simultaneously satisfy the filing obligation of the registrant under any of the following 
provisions:                                                                                                        
                                                                                            
  ☐  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)  
                                                                                            
                                                                                             
  ☐  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)  
                                                                                             
                                                                                                             
  ☐  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))  
                                                                                                             
                                                                                                             
  ☐  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))  
                                                                                                             
Securities registered pursuant to Section 12(b) of the Act:                                                        
                                                                                                    
  Title of each class               Trading Symbol(s)    Name of each exchange on which registered  
  Common Stock, Par Value $1.00     JNJ                  New York Stock Exchange                    
  0.250% Notes Due January 2022     JNJ22                New York Stock Exchange                    
  0.650% Notes Due May 2024         JNJ24                New York Stock Exchange                    
  5.50% Notes Due November 2024     JNJ24BP              New York Stock Exchange                    
  1.150% Notes Due November 2028    JNJ28                New York Stock Exchange                    
  1.650% Notes Due May 2035         JNJ35                New York Stock Exchange                    
                                                                                                    
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the          
Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 
of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting   
standards provided pursuant to Section 13(a) of the Exchange Act. ☐                                                
                           
  Item 8.01  Other Events  
                           
On August 20, 2020, Johnson & Johnson, a New Jersey corporation (the “Company”), entered into an underwriting      
agreement (the “Underwriting Agreement”) with BofA Securities, Inc. and J.P. Morgan Securities LLC, as             
representatives of the several Underwriters named therein (the “Underwriters”), pursuant to which the Company      
agreed to issue and sell to the Underwriters:                                                                      
                                                                            
  (1)  $1,000,000,000 aggregate principal amount of 0.550% Notes due 2025;  
                                                                            
                                                                            
  (2)  $1,500,000,000 aggregate principal amount of 0.950% Notes due 2027;  
                                                                            
                                                                            
  (3)  $1,750,000,000 aggregate principal amount of 1.300% Notes due 2030;  
                                                                            
                                                                            
  (4)  $1,000,000,000 aggregate principal amount of 2.100% Notes due 2040;  
                                                                            
                                                                                
  (5)  $1,000,000,000 aggregate principal amount of 2.250% Notes due 2050; and  
                                                                                
                                                                            
  (6)  $1,250,000,000 aggregate principal amount of 2.450% Notes due 2060;  
                                                                            
(collectively, the “Notes”) under the Company’s Registration Statement on Form S-3,Reg. No. 333-236499.The         
Underwriting Agreement incorporates the Underwriting Agreement Standard Provisions (Debt), dated August 20, 2020,  
which is filed as Exhibit 1.1 hereto. The issuance and sale of the Notes closed on August 25, 2020.                
                                                 
  Item 9.01  Financial Statements and Exhibits.  
                                                 
                  
  (d)  Exhibits.  
                  
                                                                                                                   
  Exhibit                                                                                                          
  No.        Description                                                                                           
  1.1        Form of Underwriting Agreement—Standard Provisions (Debt) dated as of August 20, 2020.                
 ───────────────────────────────────────────────────────────────────────────────────────────────────────────────── 
  4.1        Company Order establishing the terms of the Notes.                                                    
  5.1        Opinion of James J. Bergin, Assistant Secretary of the Company.                                       
  5.2        Opinion of Weil, Gotshal & Manges LLP.                                                                
  23.1       Consent of James J. Bergin, Assistant Secretary of the Company (included in Exhibit 5.1 of this       
             Current Report on Form 8-K).                                                                          
  23.2       Consent of Weil, Gotshal & Manges LLP (included in Exhibit 5.2 of this Current Report on Form 8-K).   
  104        The cover page of this Current Report on Form 8-K, formatted in Inline XBRL.                          
                                                                                                                   
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this
report to be signed on its behalf by the undersigned hereunto duly authorized.                                     
                                               
       Johnson & Johnson                       
  By:                     /s/ Matthew Orlando  
                          Matthew Orlando      
                          Corporate Secretary  
                                               
August 25, 2020                                                                                                    
